BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升

路透中文

Apr 22

BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升

4月22日 - ** 生物技术公司Kyverna Therapeutics KYTX.O股价盘前大涨20.6%至11.71美元

** 该公司表示，其实验性细胞疗法miv-cel在一项针对僵人综合征的中期研究中显示出强劲的疗效，僵人综合征是一种罕见的神经系统疾病，会导致严重的肌肉僵硬和疼痛性痉挛

** 公司称，单剂量治疗使试验中大多数患者的行走和活动能力得到了迅速而持久的改善

** 该公司表示，81% 的患者的行走速度明显提高，约三分之二的患者在 16 周后不再需要助行器

** 该公司表示，所有患者都能停用免疫抑制药物，目前的标准疗法通常只能提供有限的缓解

** 该公司表示，该疗法的耐受性普遍良好，一些副作用可控，如暂时性白细胞计数偏低

** 截至上一交易日收盘，股价年累计上涨约 3%

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2629017577"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2629017577\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2629017577?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-04-22 18:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629017577","market":"us","top_or_hot":-1,"title":"BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升</title></head><body><p><span>4月22日</span><span> - </span>** <a href=\"https://laohu8.com/S/000504\">生物</a>技术公司<a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> <span>KYTX.O</span>股价盘前大涨20.6%至11.71美元</p><p>** 该公司表示，其实验性细胞疗法miv-cel在一项针对僵人综合征的中期研究中显示出强劲的疗效，僵人综合征是一种罕见的神经系统疾病，会导致严重的肌肉僵硬和疼痛性痉挛</p><p>** 公司称，单剂量治疗使试验中大多数患者的行走和活动能力得到了迅速而持久的改善</p><p>** 该公司表示，81% 的患者的行走速度明显提高，约三分之二的患者在 16 周后不再需要助行器</p><p>** 该公司表示，所有患者都能停用免疫抑制药物，目前的标准疗法通常只能提供有限的缓解</p><p>** 该公司表示，该疗法的耐受性普遍良好，一些副作用可控，如暂时性白细胞计数偏低</p><p>** 截至上一交易日收盘，股价年累计上涨约 3%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2026-04-22 18:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升</title></head><body><p><span>4月22日</span><span> - </span>** <a href=\"https://laohu8.com/S/000504\">生物</a>技术公司<a href=\"https://laohu8.com/S/KYTX\">Kyverna Therapeutics</a> <span>KYTX.O</span>股价盘前大涨20.6%至11.71美元</p><p>** 该公司表示，其实验性细胞疗法miv-cel在一项针对僵人综合征的中期研究中显示出强劲的疗效，僵人综合征是一种罕见的神经系统疾病，会导致严重的肌肉僵硬和疼痛性痉挛</p><p>** 公司称，单剂量治疗使试验中大多数患者的行走和活动能力得到了迅速而持久的改善</p><p>** 该公司表示，81% 的患者的行走速度明显提高，约三分之二的患者在 16 周后不再需要助行器</p><p>** 该公司表示，所有患者都能停用免疫抑制药物，目前的标准疗法通常只能提供有限的缓解</p><p>** 该公司表示，该疗法的耐受性普遍良好，一些副作用可控，如暂时性白细胞计数偏低</p><p>** 截至上一交易日收盘，股价年累计上涨约 3%</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYTX","symbol_name":"Kyverna Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nL4T4150ZL:1","article_id":"2629017577","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629017577","pubTimestamp":1776854031,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KYTX":"Kyverna Therapeutics","BK4139":"生物科技"},"translate_title":"BUZZ-Kyverna Company Jumps as Cell Therapy for Rare Muscle Disorder Shows Strong Efficacy in Medium-Term","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYTX":0.9},"content_text":"BUZZ-Kyverna公司因罕见肌肉疾病细胞疗法在中期阶段显示出强劲疗效而跃升4月22日 - ** 生物技术公司Kyverna Therapeutics KYTX.O股价盘前大涨20.6%至11.71美元** 该公司表示，其实验性细胞疗法miv-cel在一项针对僵人综合征的中期研究中显示出强劲的疗效，僵人综合征是一种罕见的神经系统疾病，会导致严重的肌肉僵硬和疼痛性痉挛** 公司称，单剂量治疗使试验中大多数患者的行走和活动能力得到了迅速而持久的改善** 该公司表示，81% 的患者的行走速度明显提高，约三分之二的患者在 16 周后不再需要助行器** 该公司表示，所有患者都能停用免疫抑制药物，目前的标准疗法通常只能提供有限的缓解** 该公司表示，该疗法的耐受性普遍良好，一些副作用可控，如暂时性白细胞计数偏低** 截至上一交易日收盘，股价年累计上涨约 3%(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}